Biocon announced that it has signed a license and supply agreement with a subsidiary of China Medical Systems Holdings (CMS) for three generic formulation products in Greater China.
Under the terms of the agreement, Biocon will be responsible for the development, manufacturing and supply of the products. CMS will be responsible for registration and commercialisation of the products in China.
The initial term of the agreement shall be for 10 years from the date of commercialisation, extendable by two years on a product basis by mutual consent. This collaboration can be extended to a broader portfolio in future.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
